Trial Profile
A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study of the Prevention of Infection With Mycobacterium Tuberculosis Among Adolescents Who Have Previously Received BCG
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2021
Price :
$35
*
At a glance
- Drugs IMM-201 (Primary)
- Indications Tuberculosis
- Focus Therapeutic Use
- Acronyms DAR-PIA
- 28 Sep 2020 Results published in the Vaccine
- 06 Apr 2020 Status changed from active, no longer recruiting to completed.
- 02 Dec 2019 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.